Literature DB >> 8578410

Metronidazole: utilization in the obstetric and gynecologic patient.

J R Schwebke1.   

Abstract

BACKGROUND: Obstetric and gynecologic complications associated with bacterial vaginosis and trichomoniasis have heightened awareness of these conditions, and thus metronidazole's role in obstetric and gynecologic practice continues to increase. GOAL OF THIS STUDY: To review the clinical indications for metronidazole in the obstetric and gynecologic setting, as well as the pharmacokinetics and potential adverse effects of the drug. STUDY
DESIGN: Review of the current literature concerning metronidazole. RESULTS AND
CONCLUSIONS: Metronidazole remains a valuable agent for the treatment of anaerobic and protozoal infections with little evidence of resistance. Although issues of mutagenicity and carcinogenicity remain theoretical concerns, current data do not support the existence of these risks in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578410

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  7 in total

Review 1.  Fertility and pregnancy in inflammatory bowel disease.

Authors:  E Alstead
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 2.  Drug targets and mechanisms of resistance in the anaerobic protozoa.

Authors:  P Upcroft; J A Upcroft
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

3.  Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis.

Authors:  Xin Wang; Tatiana N Nanovskaya; Ying Zhan; Susan M Abdel-Rahman; Marlo Jasek; Gary D V Hankins; Mahmoud S Ahmed
Journal:  J Matern Fetal Neonatal Med       Date:  2010-07-07

Review 4.  Management of Inflammatory Bowel Disease During Pregnancy.

Authors:  Ariella Bar-Gil Shitrit; Sorina Grisaru-Granovsky; Ami Ben Ya'acov; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-04-11       Impact factor: 3.199

Review 5.  Management of inflammatory bowel disease in the pregnant patient.

Authors:  Flavio M Habal; Nikila C Ravindran
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

6.  The 1998 CDC Sexually Transmitted Diseases Treatment Guidelines.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.663

Review 7.  Metronidazole vaginal gel 0.75% (MetroGel-Vaginal): a brief review.

Authors:  A M Wain
Journal:  Infect Dis Obstet Gynecol       Date:  1998
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.